Positioned to Accelerate

35th Annual J.P. Morgan

Healthcare Conference
Robert Palmisano, President & CEO
January 9, 2017

0
 Cautionary Note Regarding Forward-Looking Statements
This presentation includes forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking
statements generally can be identified by the use of words such as anticipate, expect, intend, could, may, will, believe,
estimate, look forward, forecast, goal, target, project, continue, outlook, guidance, future, other words of similar meaning
and the use of future dates. Forward-looking statements in this presentation include, but are not limited to, anticipated sales and cost
synergies and dis-synergies and the timing thereof; the companys expectations regarding its product pipeline and the benefits of its
merger with Tornier and integration efforts and progress; the effects of the recently announced metal-on-metal Master Settlement
Agreement and settlement agreement with the three settling insurers; and the companys ability to achieve its key financial goals.
Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement
contained in this presentation is subject to risks and uncertainties that could cause actual results to differ materially from those expressed
or implied by such statement. Applicable risks and uncertainties include, among others, the failure to integrate the businesses and realize
net sales synergies and cost savings from the merger with Tornier or delay in realization thereof; operating costs and business disruption
as a result of the merger, including adverse effects on employee retention and sales force productivity and on business relationships with
third parties; integration costs; actual or contingent liabilities; adverse effects of diverting resources and attention to providing transition
services to the purchaser of the large joints business; the adequacy of the companys capital resources and need for additional financing;
the timing of regulatory approvals and introduction of new products; physician acceptance, endorsement, and use of new products; failure
to achieve the anticipated benefits from approval of AUGMENT Bone Graft; the effect of regulatory actions, changes in and adoption of
reimbursement rates; product liability claims and product recalls; pending and threatened litigation; risks associated with the Master
Settlement Agreement and settlement agreement with the three settling insurers; risks associated with international operations and
expansion; fluctuations in foreign currency exchange rates; other business effects, including the effects of industry, economic or political
conditions outside of the companys control; reliance on independent distributors and sales agencies; competitor activities; changes in tax
and other legislation; and the risks identified under the heading Risk Factors in Wrights Annual Report on Form 10-K for the year ended
December 27, 2015 filed by Wright with the SEC on February 23, 2016 and Wrights Quarterly Report on Form 10-Q for the quarter ended
September 25, 2016 filed by Wright with the SEC on November 2, 2016. Investors should not place considerable reliance on the forward-
looking statements contained in this presentation. Investors are encouraged to read Wrights filings with the SEC, available at
www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this presentation speak only
as of the date of this presentation, and Wright undertakes no obligation to update or revise any of these statements. Wrights business is
subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give
careful consideration to these risks and uncertainties.

1
 Note on Non-GAAP Financial Measures
Wright uses non-GAAP financial measures, including combined pro forma constant currency net sales,
gross margin from continuing operations, as adjusted, and EBITDA from continuing operations, as adjusted.
Wrights management team believes that the presentation of these measures provides useful information to
investors and that these measures may assist investors in evaluating the companys operations, period over
period. While pro forma data gives effect to the merger as if it had occurred on the first day of fiscal 2015
and enhances comparability of financial information between periods, pro forma data is not indicative of the
results that actually would have been obtained had the merger occurred on the first day of 2015. EBITDA is
calculated by adding back to net income charges for interest, income taxes and depreciation and
amortization expenses. While it is not possible to reconcile the adjusted EBITDA forecast in this presentation
to the nearest metric under U.S. generally accepted accounting principles (GAAP) of the combined business
without unreasonable effort, the adjusted EBITDA forecast excludes non-cash stock based compensation
expense and non-operating income and expense, as well as the expected impact of such items as inventory
step-up amortization, charges associated with product rationalization initiatives, transaction and transition
costs, all of which may be highly variable, difficult to predict and of a size that could have substantial impact
on the combined companys reported results of operations for a period. Investors should consider these non-
GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial
performance prepared in accordance with GAAP. Reconciliations of the non-GAAP financial measures used
in this presentation to most comparable GAAP measures can be found on our website.

2
Leader in 3 of the Fastest-Growing
Orthopaedic Markets
UPPER EXTREMITIES | LOWER EXTREMITIES | BIOLOGICS

~$8B #1
Global extremities/ Wright Medical position
biologics market in extremities market

~2X
Wright growth rate vs.
the market

3
Wright Medical One Year Post-Merger:
Tremendous, Measurable Progress
Completed over 80% of ~300 integration milestones
Completed integration of global sales forces, minimal disruption
Co-located most of our major international markets, consolidated them
onto one ERP system
Enjoyed better-than-expected timing of revenue dis-synergies
Ahead of schedule on cost synergies, anticipate ~$25M in 2016
Materially improved balance sheet
Significant opportunities to continue to improve inventory, instrument set
utilization and DSOs
Successful sale of our European hip/knee business
Addressed significant metal-on-metal hip litigation uncertainty with
Master Settlement Agreement

And, while we accomplished these significant initiatives

We increased our core business at ~2x market growth rates.
4
Differentiators
That Matter

Recognized Strong
leader in Global footprint Strong R&D emphasis
high-growth with the largest Leading pipeline on medical
extremities specialized technologies education
& biologics direct sales in upper and
market force in the U.S. lower extremities
portfolio

THE

ONLY
PLAYER WITH A SINGULAR FOCUS
ON
EXTREMITIES-BIOLOGICS
5
2017 Strategic Priorities for Growth

Revenue Key Priorities Cash

1. Selectively expand US sales force, ~85 1. Complete integration and realize cost
new direct, quota-carrying reps synergies
2. PerFORM Reversed Glenoid launch
Vision 2. Improve inventory, instruments and
and continue SIMPLICITI rollout Your First Choice in DSO efficiency
3. Continue AUGMENT Bone Graft Extremities & Biologics 3. Leverage SG&A
rollout

Key Financial Objectives

Mid-teens global Adj. Gross Margins in Expand EBITDA
revenue growth, high 70s% range margins to ~20% by
excluding dis-synergies 2018-2019
Contents are Confidential Wright 6
Wright Extremities: In a High-Growth
Market, Were at ~2X Market Growth Rate
Extend leadership position Accelerate foot & ankle Continued AUGMENT launch
in shoulder with new product growth through market contribution; Leverage
launches and increase sales expansion and sales opportunities for selling biologics
force productivity force optimization across expanded upper and
lower extremities portfolio

UPPER LOWER
BIOLOGICS
EXTREMITIES EXTREMITIES
MARKET
MARKET MARKET

8 9% 8 10% 5 6%
CAGR CAGR CAGR

$2.7B $3.7B $1.7B $2.8B $1.1B $1.4B

2014 2018 2014 2018 2014 2018

Available Market ~$8B

Multiple continued growth opportunities

7
Strong new
product pipeline
Upper Extremities
to drive growth SIMPLICITI Shoulder System (in rollout)
PerFORM Reversed Glenoid (anticipated 1H17)
opportunities BluePrint 3D Planning (anticipated staged 1Q/2Q17)

Lower Extremities
INFINITY Total Ankle System (in rollout)
SALVATION Limb Salvage System (in rollout)
SALVATION Limb Salvage Line Extensions (anticipated 2H17)
INVISION Revision Ankle System (anticipated 3Q17)
ORTHOLOC 3Di Ankle Fracture LP System (anticipated 4Q17)

Biologics
AUGMENT Bone Graft (in rollout)
AUGMENT Injectable Bone Graft (pursuing PMA-
Supplement with Panel Track)

2016 2017 2018

8
SIMPLICITI Shoulder:
a highlight of our upper extremities product portfolio

99% OF THE PEOPLE WHO HAVE

True Bone Preservation
Canal-sparing design provides
maximal bone preservation and
early intervention options
A SHOULDER REPLACEMENT FOR
ARTHRITIS GET PAIN RELIEF AND SAY
THEY WISH THEY HAD DONE IT SOONER.
Farmer KW, Hammond JW, Queale WS, Keyurapan E, McFarland EG. Shoulder arthroplasty versus
hip and knee arthroplasties: a comparison of outcomes. Clin Orthop Rel Res 2007;455:183-9.

Simplified Anatomic
Alignment
Fewer variables while increasing
accuracy and reproducibility

Opens new market

category
Expands patient pool surgeons
willing to treat

MARKET OPPORTUNITY (U.S.):

$200M-$250M 9
Product Pipeline: Upper Extremities

Launched: JUN 2016 PerFORM+ Glenoid

First anatomically shaped Glenoid for treating
patients with difficult glenoid anatomy

Anticipated Launch:
1H 2017
PerFORM Reversed Glenoid
Anatomically shaped Reversed Glenoid with porous metal
fixation for treating patients with difficult glenoid anatomy

Anticipated Launch:
Staged 1Q/2Q 2017
BLUEPRINT 3D Planning Software + PSI
Surgeon controlled, patient-specific instrumentation,
allows for accurate positioning of glenoid implant,
visualized bone preservation
US IDE clinical trial
underway PyroCarbon Humeral Head Clinical Study
Proprietary pyrocarbon material closely matches characteristics of bone while
providing low friction, wear resistant articulating surface to extend implant life

BluePrint 3D Planning Software is cleared for use with the Aequalis PerFORM and PerFORM+ Glenoids.
10
INBONE & INFINITY: completing the options
Total Ankle Replacement
Continuum of Care
Designed to relieve pain and
preserve motion in arthritic
ankle joint

High growth, underserved

market

Powered by accuracy of
PROPHECY patient
specific guides

INVISION revision ankle

CURRENT MARKET (U.S.): ~$90M

MARKET OPPORTUNITY (U.S.): ~$500M 11
SALVATION Limb Salvage:
promising new lower extremities product portfolio
THERE ARE AN ESTIMATED 51,000 NEW
CHARCOT PATIENTS PER YEAR IN U.S. ITS
A GLOBAL EPIDEMIC WITH RAPID GROWTH.
http://www.diiabetes.org

First comprehensive solution

for Charcot arthropathy and
advanced midfoot reconstruction
Fusion Bolts &
Large, underserved market Beams

High ASP and resistant to Plating

price pressure System

Full rollout in progress

External Fixator

CURRENT MARKET (U.S.):

$60M-$80M 12
 AUGMENT THE FIRST AND ONLY PROVEN ALTERNATIVE TO
AUTOGRAFT IN ANKLE AND HINDFOOT ARTHRODESIS
Bone Graft
Proven
Level 1 evidence of safety and effectiveness
as a replacement to autograft in the largest
F&A clinical trial ever conducted

Labeled
Class III combination product specifically proven
in, and labeled for, ankle and hindfoot arthrodesis
via a rigorous PMA regulatory pathway

Unique
The only biologic product specifically engineered,
proven, and approved for ankle and hindfoot fusions
CURRENT LITERATURE SUGGESTS
Safe
Proven safe through multiple clinical trials and OVERALL NONUNION RATES FOR
successful commercial use since 2009 in Canada ANKLE/HINDFOOT FUSIONS
and 2011 in Australia and New Zealand, while ARE ROUGHLY 10-15%.
eliminating the proven risks, morbidities, and costs
Frey C et al, FAI, 1994; Easley ME et al, JBJS (Am), 2000; Papa J, et al, JBJS (Am), 1993
associated with autograft harvest

MARKET OPPORTUNITY (U.S.):

BIOLOGICS ~$300M 13
Product Pipeline: Lower Extremities and
Biologics

Anticipated Launch:
2H 2017 SALVATION Limb Salvage Line Extensions

Anticipated Launch:
3Q 2017
INVISION Revision Ankle System

Anticipated Launch:
4Q 2017 Next Gen ORTHOLOC 3Di Ankle Fracture LP System

Anticipated Launch:
TBD AUGMENT Injectable Bone Graft
PMA-Supplement with Panel Track*
* Panel Track Supplement does not necessarily result in a panel meeting. It affords FDA additional time to review the submission
beyond 180 days. The current average for Panel Track Supplement review and approval is 300+ days.

14
Clear post-merger path to high growth and
profitability
with more levers coming into play
STEP STEP STEP

1 2 3

Sustain revenue Deliver cost Leverage existing

growth/ minimize synergies of ~$40M resources
disruption to $45M

MID TEENS GROWTH adjusted

once integrated ~20% EBITDA margins
by 2018-2019
ADJ. GROSS MARGINS
high 70s% range
15
Sustained revenue growth
with minimal disruption

Complementary Product Portfolios

Upper Extremities
percentage of revenue

81%
Anticipated
7% Revenue
Dis-Synergies:
~$14M in
Lower Extremities 1H2017
percentage of revenue From sales force integration (~$10M)
and incremental intl Salto ankle

69% divestiture (~$4M)

13%
Based on 2015 YTD pro-forma revenue from continuing operations 16
Clear line of sight to deliver post-merger
cost synergies into 2017-2018
Key
Synergy Public company expenses
Areas
Overlapping support functions Anticipated
Overlapping systems
Cost Synergies
by 2018-2019:
Vendor consolidation ~$40M-$45M
Process improvement

COMPLETED OVER 80% OF ANTICIPATED ~$25M OF COST

~300 INTEGRATION MILESTONES SYNERGIES IN YEAR 1

17
Opportunity for Significant Leverage Going
Forward >50% of operating expense is highly leverageable

Key Drivers Sizing the Opportunity

% of
Return on previous Op Expense
investments
AUGMENT Bone Graft
14% Depreciation
Amortization } Non-
EBITDA
Re-invest
International Expansion
Sales Force
30%
R&D
Sales Force } at rate of
sales
Medical Education
Hubs
Leverage existing infrastructure
24%
Sales Management
Marketing
Medical Education
} Leverage

32%
Distribution
G&A } Significant
Leverage

100% Total Operating Expense 18

2016 Balance Sheet Improvements
Efforts to date focused on legacy Wright business

> 100 days

Inventory improvement in
Legacy Wright

Annual ~$6M Reduction in

Instrument Legacy Wright
Capital Spend

7.5 day
Gross DSO improvement in
US DSO

19
Advancing toward our goals
YTD 3Q 2016 GOALS
Non-GAAP Once Integrated
Results from With Tornier
Continuing Ops.
SALES
GROWTH 12%* (includes Mid teens
revenue dis-synergies)

ADJ.
GROSS 78.4% High 70s% range
MARGIN
ADJ.
EBITDA 6% Adj. EBITDA margins
MARGIN approximately 20%
by 2018-2019

* Pro forma constant currency sales growth from

continuing operations 20
Wright Medical:
Positioned to Outperform

Core extremities business growing at 2X the market

Multiple growth drivers via new product pipeline

Post-merger business momentum is increasing

On a faster path to profitability,

with a stronger financial profile

21
22
For additional information,
please contact:

Julie Tracy
Chief Communications Officer
julie.tracy@wright.com
(901) 290-5817

www.wright.com NASDAQ: WMGI

23
 Positioned to Accelerate

35th Annual J.P. Morgan

Healthcare Conference
Robert Palmisano, President & CEO
January 9, 2017

24